To further evaluate the efficacy of the PI3K inhibitor and combined gefitinib and MEN1611 treatment in vivo, we generated xenograft mouse models with HCC827, RA1, RB1, and RA2 NSCLC cells as described in the Materials and Methods. This evidence concerns the gene PIK3CB and non-small cell lung carcinoma.